NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Urology: Metastatic HSPC treatment intensification (STAMPEDE abiraterone)

Free question published 28 October 2026

UrologyMetastatic HSPC treatment intensification (STAMPEDE abiraterone)

A 70-year-old man presents with newly diagnosed metastatic hormone-sensitive prostate cancer with multiple bone metastases. His performance status is 1 and he has well-controlled hypertension but no significant cardiac history. He is starting long-term androgen deprivation therapy and is not keen on chemotherapy because of the alopecia and neutropenia risk. Which addition to androgen deprivation therapy has the strongest evidence of an overall survival benefit while avoiding cytotoxic chemotherapy?

  1. ABicalutamide monotherapy as anti-androgen treatment for prostate cancer
  2. BEstramustine phosphate
  3. CZoledronic acid alone
  4. DAbiraterone acetate plus prednisolone
  5. ERadium-223 dichloride

Why D is correct

In the STAMPEDE abiraterone comparison, adding abiraterone acetate plus prednisolone to androgen deprivation therapy in men starting long-term hormone therapy significantly improved overall survival (hazard ratio for death 0.63). It is an oral, non-cytotoxic intensification option, making it the best choice for a man declining chemotherapy.

And why the others are not

  • AIncorrect: bicalutamide monotherapy is inferior to ADT-based intensification and lacks an equivalent survival benefit here.
  • BIncorrect: estramustine is not a standard intensification agent in metastatic hormone-sensitive prostate cancer.
  • CIncorrect: zoledronic acid did not improve survival when added to ADT in STAMPEDE.
  • EIncorrect: radium-223 is used in castration-resistant disease with symptomatic bone metastases, not as upfront HSPC intensification.

Source STAMPEDE — Abiraterone added to ADT in hormone-naive prostate cancer — James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338-351.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing